[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yuanyuan Wu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100591246","the-alternative-effects-of-electroacupuncture-in-the-treatment-of-trigeminal-neuralgia-100591246",false,"NCT06977932","The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia","The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia: Protocol for a Multicentre Randomised Controlled Trial","Diagnostic Criteria\n\nDiagnosis was based on the criteria for trigeminal neuralgia (TN) as defined in the third edition of the International Classification of Headache Disorders (ICHD-3) published by the International Headache Society (IHS) in 2018. The diagnostic criteria included:\n\n1. recurrent unilateral facial pain occurring in the distribution of one or more divisions of the trigeminal nerve, without radiation outside the trigeminal territory, and meeting criteria (2) and (3);\n2. pain presenting with all of the following characteristics:\n\n   ① paroxysmal attacks lasting from a few seconds to 2 minutes;\n\n   ② severe intensity;\n   * electric shock-like, stabbing, or sharp quality;\n3. pain triggered by innocuous stimuli within the affected trigeminal distribution;\n4. exclusion of other facial pain disorders classified in ICHD-3.\n\n   Inclusion Criteria\n\n   All of the following criteria had to be met for study enrollment:\n   * fulfillment of the TN diagnostic criteria as stated above;\n\n     * age between 18 and 80 years, inclusive, irrespective of sex;\n\n       * receiving a stable daily dose of carbamazepine (200-400 mg); ④ consciousness clear, with intact pain perception and discrimination, and able to communicate effectively; ⑤ voluntary participation with written informed consent provided by the patient or their legal guardian\u002Fauthorized representative.\n\n   Exclusion Criteria\n\n   Participants were excluded if they met any of the following:\n   * comorbid epilepsy, head injury, or other relevant neurological disorders;\n\n     * significant impairment of cardiac, hepatic, or renal function;\n\n       * cognitive dysfunction, aphasia, psychiatric conditions, or inability to cooperate with treatment;\n\n         * poorly controlled hypertension or hyperglycemia;\n\n           ⑤ recent diagnosis of severe anxiety or depression;\n\n           ⑥ pregnancy or lactation;\n\n           ⑦ presence of a cardiac pacemaker or other contraindications to electroacupuncture therapy;\n\n           ⑧ current participation in another clinical trial.","ALL","18 Years","80 Years",{"count":20,"type":21},126,"ESTIMATED","INTERVENTIONAL",[24],"NA","Trigeminal neuralgia (TN), characterized by its refractory nature and recurrence, frequently leads to anxiety, depression, and insomnia, thereby significantly diminishing patients' quality of life and potentially inducing self-harm. Carbamazepine (CBZ) is the first-line medication for TN, yet it presents adverse effects such as addiction and the absence of analgesic effects upon cessation. Acupuncture, particularly electroacupuncture（EA）, has demonstrated efficacy in TN treatment, although its therapeutic outcomes are influenced by various factors. Consequently, this study aims to evaluate the clinical efficacy of EA for TN and its potential as an alternative to CBZ treatment.",[27],"Trigeminal Neuralgia",[29,30],"Electroacupuncture","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-03-02",{"date":34,"type":35},"2026-03-05","ACTUAL",{"date":37,"type":21},"2026-03-01",{"date":39,"type":21},"2028-12-31",{"name":41,"class":42},"Yuanyuan Wu","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100598674","the-synergism-and-attenuation-effects-of-electroacupuncture-in-the-treatment-of-trigeminal-neuralgia-100598674","NCT07074561","The Synergism and Attenuation Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia","The Synergism and Attenuation Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia：Protocol for a Multicentre Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants must meet all of the following criteria to be eligible for this study:\n\n  1. Met the diagnostic criteria for trigeminal neuralgia (TN) as defined in the International Classification of Headache Disorders, 3rd edition (ICHD-3) published by the International Headache Society (IHS) in 2018.\n  2. Between 18 and 75 years old (inclusive), regardless of gender;\n  3. Currently prescribed carbamazepine (400-800 mg\u002Fday) or oxcarbazepine (800-1600 mg\u002Fday);\n  4. Conscious, alert, and capable of perceiving\u002Fdifferentiating pain, with basic communication abilities;\n  5. Signed informed consent form and voluntary participation in the study.\n\nExclusion Criteria:\n\n* Patients meeting any of the following criteria were excluded:\n\n  1. Patients with epilepsy, head injury, or other relevant neurological disorders;\n  2. Patients with severe cardiac, hepatic, or renal impairment;\n  3. Patients with cognitive dysfunction, aphasia, psychiatric disorders, or those unable to cooperate with treatment;\n  4. Patients with poorly controlled hypertension or hyperglycemia;\n  5. Patients with a recent diagnosis of severe anxiety or depression;\n  6. Pregnant or breastfeeding patients;\n  7. Patients with pacemakers or other contraindications to electroacupuncture;\n  8. Patients concurrently enrolled in other clinical studies.","75 Years",{"count":52,"type":21},28,[24],"Trigeminal neuralgia (TN), characterized by its refractory nature and recurrence, frequently leads to anxiety, depression, and insomnia, thereby significantly diminishing patients' quality of life and potentially inducing self-harm. Carbamazepine (CBZ) is the first-line medication for TN, yet it presents adverse effects such as addiction and the absence of analgesic effects upon cessation. Acupuncture, particularly electroacupuncture（EA）, has demonstrated efficacy in TN treatment, although its therapeutic outcomes are influenced by various factors. This multicenter, randomized controlled trial aims to evaluate the synergistic efficacy-enhancing and toxicity-reducing effects of the optimized protocol when combined with carbamazepine (CBZ) in treating trigeminal neuralgia (TN), thereby proposing novel therapeutic refinements for electroacupuncture treatment regimens in TN management.",[27],[29,57],"Carbamazepine","2025-07-10",{"date":60,"type":35},"2025-07-20",{"date":60,"type":21},{"date":63,"type":21},"2025-12-31",{"name":41,"class":42},""]